HIGHLIGHTS
- who: Nawal Al Kaabi from the Khalifa University New Vaccine Research, Beijing, China have published the article: Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial, in the Journal: NATURE COMMUNICATIONS NATURE COMMUNICATIONS of January/31,/2022
- what: Findings from this trial show that the heterologous prime-boost vaccination with one dose of NVSI-06-08 following two doses of BBIBP-CorV was safe, tolerant, and immunogenic in healthy adults. The studies show that booster vaccination of NVSI-06-08 elicited a potent cross-neutralizing . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.